Positive phase 2a Results, enhancing IP and trial strategy

Tryptamine Therapeutics Limited (ASX: TYP) has reported positive results from its Phase 2a trial of TRP-8802, an oral psilocybin formulation, in treating fibromyalgia, conducted in collaboration with the University of Michigan. Presented at the IASP 2024 World Congress, the trial showed that 100% of participants experienced significant reductions in pain severity, sleep disturbances, and pain interference one month after treatment, alongside improved quality of life, anxiety, and cognitive abilities. These encouraging findings highlight the potential of psychedelic-assisted therapy for fibromyalgia, a condition affecting millions with limited treatment options. The results also strengthen Tryp's intellectual property position and will inform plans for a subsequent Phase 2 trial using TRP-8803, anticipated to start in H1 2025.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com